Litcius/Paper detail

Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial

Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, Ian Kirkwood, Narjess Ayati, Narjess Ayati, Michael S. Hofman, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler, Louise Emmett, Nathan Papa, Shalini Subramaniam, Megan Crumbaker, Andrew Nguyen, Anthony M. Joshua, Shahneen Sandhu, Andrew Weickhardt, Sze-Ting Lee, Siobhan Ng, Roslyn J. Francis, Jeffrey C. Goh, David A. Pattison, Thean Hsiang Tan, M. L. Bills, Thean Hsiang Tan, Ian Kirkwood, Narjess Ayati, Ian D. Kirkwood, Michael S. Hofman, Andrew Martin, Hayley Thomas, Ian D. Davis, Martin R. Stockler, Nicole Tankard, Samantha R. Oakes, Alison Y. Zhang, J. C. Thompson, Thida Thein, Thomas W. Cusick, Shikha Sharma, Thomas W. Cusick, Shikha Sharma

2025The Lancet Oncology27 citationsDOI

Topics & Concepts

Prostate cancerMedicineOncologyOpen labelInternal medicinePredictive valuePhases of clinical researchUrologyCancerRandomized controlled trialClinical trialProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentRadiopharmaceutical Chemistry and Applications
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial | Litcius